1. Home
  2. ICG vs LUNG Comparison

ICG vs LUNG Comparison

Compare ICG & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intchains Group Limited

ICG

Intchains Group Limited

HOLD

Current Price

$0.92

Market Cap

49.4M

Sector

Technology

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.54

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICG
LUNG
Founded
2017
1995
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Industrial Specialties
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.4M
57.9M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ICG
LUNG
Price
$0.92
$1.54
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$5.25
$5.38
AVG Volume (30 Days)
69.2K
590.9K
Earning Date
05-21-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$6.80
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.60
$1.13
52 Week High
$3.22
$3.88

Technical Indicators

Market Signals
Indicator
ICG
LUNG
Relative Strength Index (RSI) 55.07 56.81
Support Level $0.63 $1.22
Resistance Level $1.36 $1.67
Average True Range (ATR) 0.09 0.12
MACD 0.04 0.02
Stochastic Oscillator 79.39 89.06

Price Performance

Historical Comparison
ICG
LUNG

About ICG Intchains Group Limited

Intchains Group Ltd is an inventive altcoins development company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies and the active development of inventive Web3 applications. The company offers high-performance mining products including altcoin mining machines incorporating its ASIC chips that have high computing power and superior power efficiency, ASIC chips and ancillary software and hardware, all of which cater to the evolving needs of the blockchain industry. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: